Respiratory viruses

Infectious Diseases: Third Edition

Volumn 2, Issue , 2010, Pages 1598-1608

  Schaffer, Kirsten ^a   La Rosa, Alberto M ^b   Whimbey, Estella ^c  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929659105     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04579-7.00162-3     Document Type: Chapter

References (86)

1. Russell W.C. Update on adenovirus and its vectors. J Gen Virol 2000, 81(Pt 11):2573-2604.
2. Schilham M.W., Claas E.C., van Zaane W., et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis 2002, 35:526-532.
3. Suparno C., Milligan D.W., Moss P.A., et al. Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management. Leuk Lymphoma 2004, 45:873-885.
4. Kojaoghlanian T., Flomenberg P., Horwitz M.S. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003, 13:155-171.
5. La Rosa A.M., Champlin R.E., Mirza N., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001, 32(6):871-896.
6. Sloots T.P., Whiley D.M., Lambert S.B., Nissen M.D. Emerging respiratory agents: new viruses for old diseases?. J Clin Virol 2008, 42:233-243.
7. Monto A.S., Lim S.K. The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection. J Infect Dis 1974, 129:271-336.
8. Peiris J., Lai S., Poon L., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 363:1319-1325.
9. Ksiazek T.G., Erdman D., Goldsmith C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348:1947-1958.
10. Weiss S.R., Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Micro Mol Biol Rev 2005, 69(4):635-664.
11. van Elden L.J., van Loon A.M., van Alphen F., et al. Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis 2004, 189:652-657.
12. Chilvers M.A., McKean M., Rutman A., Myint B.S., Silverman M., O'Callaghan C. The effects of coronavirus on human nasal ciliated respiratory epithelium. Eur Respir J 2001, 18(6):965-970.
13. Siegel J.D., Rhinehart E., Jackson M., Chiarello L. Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings 2007 2007, the Healthcare Infection Control Practices Advisory Committee, Online. Available:. http://www.cdc.gov/ncidod/dhqp/gl_isolation.html.
14. Seto W.H., Tsang D., Yung R.W., et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003, 361:1519-1520.
15. Bradburne A.F., Bynoe M.L., Tyrrell D.A. Effects of a 'new' human respiratory virus in volunteers. BMJ 1967, 3:767-769.
16. Gu J., Gong E., Zhang B., et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005, 202:415-424.
17. Peiris J.S., Guan Y., Yuenk Y. Severe acute respiratory syndrome. Nature Med 2004, 10:S88-S97.
18. Bing Chua K., Voon K., Crameri G., et al. Identification and characterization of a new orthoreovirus from patients with acute respiratory infections. PloS ONE 2008, 3(11):1-7.
19. Selb B., Weber B. A study of human reovirus IgG and IgA antibodies by ELISA and Western blot. J Virol Methods 1994, 47:15-26.
20. Rosen L., Evans H.E., Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963, 77:29-37.
21. Lau S.K.P., Yip C.C.Y., Tsoi H.-W., et al. Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children. J Clin Microbiol 2007, 45(11):3655-3664.
22. Kaiser L., Aubert J.D., Pache C., et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006, 174:1392-1399.
23. Miller E.K., Lu X., Erdman D.D., et al. Rhinovirus-associated hospitalizations in young children. J Infect Dis 2007, 195:773-781.
24. Turner R.B. Rhinovirus: more than just a common cold virus. J Infect Dis 2007, 195:765-786.
25. Gwaltney J.M.J., Hendley J.O., Phillips C.D., Bass C.R., Mygind N., Winther B. Nose blowing propels nasal fluid into the paranasal sinuses. Clin Infect Dis 2000, 30(2):387-391.
26. Gwaltney J.M.J., Phillips C.D., Miller R.D., Riker D.K. Computed tomographic study of the common cold. N Engl J Med 1994, 330(1):25-30.
27. Patick A.K. Rhinovirus chemotherapy. Antivir Res 2006, 71:391-446.
28. Hayden F.G., Kaiser D.L., Albrecht J.K. Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother 1988, 32:224-230.
29. Patick A.K., Brothers M.A., Maldonado F., et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 2005, 49(6):2267-2275.
30. Turner R.B., Wecker M.T., Pohl G., et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 1999, 281(19):1797-1804.
31. Hayden F.G., Herrington D.T., Coats T.L., et al. Pleconaril respiratory infection study group. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of two double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003, 36(12):1523-1532.
32. Hall C.B. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001, 344:1917-1938.
33. Breese Hall C., Weinberg G.A., Iwane M.K., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360(6):588-598.
34. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352(17):1749-1759.
35. Hall C.B., Douglas R.G.J. Modes of transmission of respiratory syncytial virus. J Pediatr 1981, 99(1):100-103.
36. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163(4):693-778.
37. Garcia R., Raad I., Abi-Said D., et al. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol 1997, 18(6):412-416.
38. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997, 99(1):93-99. Anonymous.
39. Atkins J.T., Karimi B.H., McDavid G., Shim S. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immune globulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost. Pediatr Infect Dis J 2000, 19(2):138-143.
40. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Virus Res 1998, 55(2):167-176. Anonymous.
41. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003, 112:1442-1446. Committee on Infectious Diseases and Committee on Fetus and Newborn.
42. Schrand L.M., Elliott J.M., Ross M.B., et al. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother 2001, 35(10):1186-1193.
43. O'Shea T.M., Sevick M.A., Givner L.B. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants. Pediatr Infect Dis J 1998, 17(7):587-593.
44. Joffe S., Ray G.T., Escobar G.J., Black S.B., Lieu T.A. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999, 104(3 Pt 1):419-427.
45. Thomas M., Bedford-Russell A., Sharland M. Hospitalization for RSV infection in ex-preterm infants - implications for use of RSV immune globulin. Arch Dis Child 2000, 83(2):122-127.
46. Stevens T.P., Sinkin R.A., Hall C.B., Maniscalco W.M., McConnochie K.M. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000, 154(1):55-61.
47. McBride J.T. Pulmonary function changes in children after respiratory syncytial virus infection in infancy. J Pediatr 1999, 135(2 Pt 2):28-32.
48. Whimbey E., Champlin R.E., Couch R.B., et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996, 22(5):778-782.
49. Moler F.W., Steinhart C.M., Ohmit S.E., Stidham G.L. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group. J Pediatr 1996, 128(3):422-428.
50. Randolph A.G., Wang E.E. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract. Cochrane Database Syst Rev 2000, (2):CD000181.
51. DeVincenzo J.P., Hirsch R.L., Fuentes R.J., Top F.H.J. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant 2000, 25(2):161-225.
52. Whimbey E., Champlin R.E., Englund J.A., et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995, 16(3):393-449.
53. Henrickson K.J., Kuhn S.M., Savatski L.L. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis 1994, 18(5):770-779.
54. Counihan M.E., Shay D.K., Holman R.C., et al. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 2001, 20(7):646-653.
55. Knott A.M., Long C.E., Hall C.B. Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics. Pediatr Infect Dis J 1994, 13(4):269-273.
56. Fan J., Henrickson K.J. Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay. J Clin Microbiol 1996, 34(8):1914-1917.
57. Marx A., Gary H.E., Marston B.J., et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis 1999, 29(1):134-140.
58. Arisoy E.S., Demmler G.J., Thakar S., Doerr C. Meningitis due to parainfluenza virus type 3: report of two cases and review. Clin Infect Dis 1993, 17(6):995-997.
59. Wendt C.H., Weisdorf D.J., Jordan M.C., Balfour H.H.J., Hertz M.I. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992, 326(14):921-926.
60. Cortez K.J., Erdman D.D., Peret T.C., et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis 2001, 184(9):1093-1097.
61. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001, 98(3):573-578.
62. Hohenthal U., Nikoskelainen J., Vainionpaa R., et al. Parainfluenza virus type 3 infections in a hematology unit. Bone Marrow Transplant 2001, 27(3):295-300.
63. Whimbey E., Vartivarian S.E., Champlin R.E., Elting L.S., Luna M., Bodey G.P. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1993, 12(9):699-701.
64. Lewis V.A., Champlin R., Englund J., et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 1996, 23(5):1033-1037.
65. Vilchez R.A., McCurry K., Dauber J., et al. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis 2001, 33(12):2004-2008.
66. DeFabritus A.M., Riggio R.R., David D.S., Senterfit L.B., Cheigh J.S., Stenzel K.H. Parainfluenza type 3 in a transplant unit. JAMA 1979, 241(4):384-446.
67. Browne M.J. Comparative inhibition of influenza and parainfluenza virus replication by ribavirin in MDCK cells. Antimicrob Agents Chemother 1981, 19(5):712-715.
68. van den Hoogen B.G., de Jong J.C., Groen J., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001, 7(6):719-724.
69. Biacchesi S., Skiadopoulos M.H., Boivin G., et al. Genetic diversity between human metapneumovirus subgroups. Virology 2003, 315:1-9.
70. van den Hoogen B.G., Herfst S., Sprong L., et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004, 10:658-666.
71. Sloots T.P., Whiley D.M., Lambert S.B., Nissen M.D. Emerging respiratory agents: new viruses for old diseases?. J Clin Virol 2008, 42:233-243.
72. Williams J.V., Harris P.A., Tollefson S.J., et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004, 350:443-450.
73. Williams J.V., Wang C.K., Yang C.F., et al. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis 2006, 193:387-395.
74. Sasaki A., Suzuki H., Saito R., et al. Prevalence of human metapneumovirus and influenza virus infections among Japanese children during two successive winters. Pediatr Infect Dis J 2005, 24:905-908.
75. Chano F., Rousseau C., Laferriere C., Couillard M., Charest H. Epidemiological survey of human metapneumovirus infection in a large pediatric tertiary care center. J Clin Microbiol 2005, 43:5520-5525.
76. Peiris J.S., Tang W.H., Chan K.H., et al. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 2003, 9:628-633.
77. Laham F.R., Israele V., Casellas J.M., et al. Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. J Infect Dis 2004, 189:2047-2056.
78. Mackay I.M., Jacob K.C., Woolhouse D., et al. Molecular assays for detection of human metapneumovirus. J Clin Microbiol 2003, 41:100-105.
79. Heikkinen T., Osterback R., Peltola V., Jartti T., Vainionpaa R. Human metapneumovirus infections in children. Emerg Infect Dis 2008, 14:101-106.
80. Wyde P.R., Chetty S.N., Jewell A.M., Boivin G., Piedra P.A. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2004, 60:51-59.
81. Allander T., Tammi M.T., Eriksson M., et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 2005, 102:12891-12896.
82. Allander T. Human bocavirus. J Clin Virol 2008, 41:29-33.
83. Allander T., Jartti T., Gupta S., et al. Human bocavirus and acute wheezing in children. Clin Infect Dis 2007, 44:904-910.
84. Fry A.M., Lu X., Chittaganpitch M., et al. Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. J Infect Dis 2007, 195:1038-1045.
85. Endo R., Ishiguro N., Kikuta H., et al. Seroepidemiology of human bocavirus in Hokkaido prefecture, Japan. J Clin Microbiol 2007, 45:3218-3223.
86. Kantola K., Hedman L., Allander T., et al. Serodiagnosis of human bocavirus infection. Clin Infect Dis 2008, 46:540-546.